Company intelligence / Profile preview

Belhaven Biopharma

Ownership: Private
Development stage: Other

Overview

Belhaven Biopharma has developed Nasdepi®, a dry powder intranasal epinephrine product for the emergency treatment of anaphylaxis. Phase 1 clinical data show Nasdepi® achieves comparable or superior pharmacokinetics to standard intramuscular injection, with rapid absorption and good tolerability. The product offers advantages in shelf stability, heat resistance, ease of use, and accessibility compared to autoinjectors. The company has completed dose-confirmation studies supporting commercial dose selection and plans a pivotal biocomparability study as part of its NDA-enabling program.

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule (epinephrine)Dry powder nasal formulationDevice (nasal drug delivery device)
Industry: Biotech

Beyond the preview

Go deeper on Belhaven Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Belhaven Biopharma.

Explore the full profile